Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Serena Williams lost 31 pounds using Zepbound after traditional training failed, opening up about health, hormones, and her ...

Serena Williams sat down with the hosts of Today for a candid interview about her use of GLP-1 medication. The Olympic ...

In a candid conversation, tennis legend Serena Williams sheds light on her experience with GLP-1 medication, revealing her journey towards body positivity and health. As a mother of two and a 23-time ...

Tennis star Serena Williams' candor about her GLP-1 use may help dispel the pesky health inaccuracy that weight loss is a ...

Serena Williams reveals her use of GLP-1, Zepbound and calls out the stigma surrounding the use of the popular weight loss drug.

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The healthcare company has an injectable version of its anti-obesity candidate in ...

(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...